CytoDyn announced that its drug leronlimab will be tested in two new Phase 1-1b studies within the PRE-I-SPY platform for metastatic triple-negative breast cancer (mTNBC). These studies will evaluate leronlimab in combination with immunotherapy agents including pembrolizumab and penpulimab, alongside chemotherapy drugs, focusing on safety, tolerability, and early clinical activity signals. Enrollment is expected to start in early and mid-2027, aiming to explore leronlimab's potential in improving treatment options for this aggressive cancer subtype. The studies also include biomarker assessments to better understand treatment effects and guide future development.
The story on CytoDyn and QLHC advancing leronlimab into new PRE-I-SPY studies is presented with Health-sector market data for context. For readers following this sector, here is Pluang's snapshot as of Nov 10, 2026 19:42 WIB: Out of 150 priced Health-sector US stocks, 83 rose and 55 fell today. DNA (Ginkgo Bioworks Holdings Inc) traded at USD 12.17 with a 1-day change of -1.62% and a typical hold time of 9 days, contrasting with RVTY (Revvity Inc) at USD 163.18, which rose 1.53% but saw 100% sell order activity and a longer hold time of 14 days. RXRX (Recursion Pharmaceuticals Inc) was priced at USD 3.75, down 1.45%, with a typical hold time of 22 days and 100% buy order activity.
project44 has partnered with Snowflake to enhance supply chain decision-making through Mo, an AI-powered supply chain analyst. Mo uses project44's extensive logistics data and Snowflake Cortex AI to provide accurate, consistent answers to complex sup...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
